CALTOUX Tablet

គុណភាពព្យាបាល:

សំរាប់ព្យាបាលក្អកស្ងួត និង ក្អករមាស់បំពង់ក។

កំរិតនិងរបៀបប្រើ:

គ្រប់ករណីទាំងអស់ ត្រូវគោរពតាមវេជ្ជបញ្ជាគ្រូពេទ្យរបស់អ្នក។ មនុស្សពេញវ័យ (ចាប់ពីអាយុ15ឆ្នាំឡើង): លេបម្ដង1គ្រាប់ រាល់4ទៅ6ម៉ោងម្ដង។ កំរិតប្រើមិនត្រូវអោយលើស4គ្រាប់ក្នុង1ថ្ងៃទេ។

Symptomatic relief of dry cough and irritative cough.

Dosage and mode of administration

Adult (from 15 years of old): 1 tablet every 4-6 hours if needed.

Do not exceed 4 tablets per day.

Oral route.

The therapy duration should be a few days (limited to 5 days).

ហាមប្រើ:

- ចំពោះអ្នកងាយមានប្រតិកម្មជាមួយសារធាតុផ្សំណាមួយនៃឱសថនេះ

- ក្មេងអាយុក្រោម15ឆ្នាំ

- ក្អកដោយសារកើតហឺត

- មុខងារប្រព័ន្ធដង្ហើមខ្សោយ។

- Hypersensitivity to one of the components.

- Children under 15 years old.

- Asthmatic cough.

- Respiratory depression.

ផលរំខានខ្លះៗ: ទល់លាមក ងងុយដេក ធេងធោង វិលមុខ ក្អួត ប្រតិកម្មអាលែកហ្ស៊ីស្បែក។

Constipation, drowsiness, dizziness, nausea, vomiting, skin allergy.

អន្តរកម្មឱសថ: ការប្រើឱសថនេះដំណាលគ្នាជាមួយ MAO Inhibitors ត្រូវបានគេហាមប្រើ។

The concomitant use of this drug with MAO inhibitors is contraindicated.

ស្ត្រីមានផ្ទៃពោះ: ឱសថនេះអាចប្រើបានចំពោះស្ត្រីមានផ្ទៃពោះសំរាប់រយៈពេលខ្លីក្នុងករណីចាំបាច់តែប៉ុណ្ណោះ។

ស្ត្រីបំបៅដោះ: ក្នុងករណីបំបៅដោះ ហាមប្រើឱសថនេះ។

Pregnancy:

This drug can be prescribed for a brief use only if necessary.

Breast-feeding:

Contraindicated.

- ហាមប្រើជាតិអាល់កុលពេលកំពុងព្យាបាល។

- បើក្អកនៅតែកើតមាន ឬធ្ងន់ធ្ងរទៅៗ បន្ទាប់ពីលេបឱសថនេះនៅកំរិតប្រើធម្មតា មិនត្រូវបង្កើនកំរិតប្រើទេ ត្រូវពិគ្រោះជាមួយគ្រូពេទ្យដើម្បីពិនិត្យរោគសញ្ញាគ្លីនិកឡើងវិញ។

- កែតំរូវកំរិតប្រើចំពោះអ្នកជំងឺថ្លើម។

- បើសិនអ្នកបើកបរ ឬបញ្ជាម៉ាស៊ីន ត្រូវដឹងថាអ្នកប្រើឱសថនេះអាចធ្វើអោយងងុយដេក។

- It is not recommended to drink alcoholic beverages during the treatment.

- If cough persists or get worse after the administration of this drug at usual dose, do not increase the dose, but consult your doctor for reexamining of the clinical situation.

- Adjust the dose in case of hepatic insufficiency.

- If you drive or operate machinery, you should be aware that the use of this drug can cause drowsiness.

Cefdinir is bactericidal and has the same mode of action as other beta-lactam antibiotics (such as penicillins) but is less susceptible to penicillinases. It disrupts the synthesis of the peptidoglycan layer of bacterial cell walls. The peptidoglycan layer is important for cell wall structural integrity. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by transpeptidases known as penicillin-binding proteins (PBPs). PBPs bind to the D-Ala-D-Ala at the end of mucopeptides (peptidoglycan precursors) to crosslink the peptidoglycan. Beta-lactam antibiotics mimic the D-Ala-D-Ala site, thereby competitively inhibiting PBP crosslinking of peptidoglycan. This leads to the death of the bacteria.

Cefdinir is active against a very wide spectrum of bacteria, including:

Aerobic Gram-Positive Microorganisms

Staphylococcus aureus (including beta-lactamase producing strains)

NOTE: Cefdinir is inactive against methicillin-resistant staphylococci.

Streptococcus pneumoniae (penicillin-susceptible strains only)

Streptococcus pyogenes

Aerobic Gram-Negative Microorganisms

Haemophilus influenzae (including beta-lactamase producing strains)

Haemophilus parainfluenzae (including beta-lactamase producing strains)

Moraxella catarrhalis (including beta-lactamase producing strains)

The following in vitro data are available, but their clinical significance is unknown. (See the package insert.)

Aerobic Gram-Positive Microorganisms

Staphylococcus epidermidis (methicillin-susceptible strains only)

Streptococcus agalactiae

Viridans group streptococci

NOTE: Cefdinir is inactive against Enterococcus and methicillin-resistant Staphylococcus species.

Aerobic Gram-Negative Microorganisms

Citrobacter diversus

Escherichia coli

Klebsiella pneumoniae

Proteus mirabilis

NOTE: Cefdinir is inactive against Pseudomonas and Enterobacter species.